Tetrahydropalmatine acts on α7nAChR to regulate inflammation and polarization of BV2 microglia.
10.19540/j.cnki.cjcmm.20250310.402
- Author:
Yan-Jun WANG
1
;
Guo-Liang DAI
1
;
Pei-Yao CHEN
1
;
Hua-Xi HANG
1
;
Xin-Fang BIAN
1
;
Yu-Jie CHEN
1
;
Wen-Zheng JU
1
Author Information
1. Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, China.
- Publication Type:Journal Article
- Keywords:
BV2 microglia;
M1/M2 polarization;
depression;
inflammation;
tetrahydropalmatine;
α7nAChR
- MeSH:
Berberine Alkaloids/chemistry*;
alpha7 Nicotinic Acetylcholine Receptor/chemistry*;
Microglia/metabolism*;
Mice;
Animals;
Cell Line;
Corydalis/chemistry*;
Humans;
Molecular Docking Simulation;
Inflammation/drug therapy*;
Nitric Oxide Synthase Type II/immunology*;
Tumor Necrosis Factor-alpha/immunology*
- From:
China Journal of Chinese Materia Medica
2025;50(11):3117-3126
- CountryChina
- Language:Chinese
-
Abstract:
Based on the α7 nicotinic acetylcholine receptor(α7nAChR), this study examined how tetrahydropalmatine(THP) affected BV2 microglia exposed to lipopolysaccharide(LPS), aiming to clarify the possible mechanism underlying the anti-depression effect of THP from the perspectives of preventing inflammation and regulating polarization. First, after molecular docking and determination of the content of Corydalis saxicola Bunting total alkaloids, THP was initially identified as a possible anti-depression component. The BV2 microglia model of inflammation was established with LPS. BV2 microglia were allocated into a normal group, a model group, low-and high-dose(20 and 40 μmol·L~(-1), respectively) THP groups, and a THP(20 μmol·L~(-1))+α7nAChR-specific antagonist MLA(1 μmol·L~(-1)) group. The CCK-8 assay was used to screen the safe concentration of THP. A light microscope was used to examine the morphology of the cells. Western blot and immunofluorescence were used to determine the expression of α7nAChR. qRT-PCR was performed to determine the mRNA levels of inducible nitric oxide synthase(iNOS), cluster of differentiation 86(CD86), suppressor of cytokine signaling 3(SOCS3), arginase-1(Arg-1), cluster of differentiation 206(CD206), tumor necrosis factor(TNF)-α, interleukin(IL)-6, and IL-1β. Enzyme-linked immunosorbent assay(ELISA) was employed to measure the levels of TNF-α, IL-6, and IL-1β in the cell supernatant. The experimental results showed that THP at concentrations of 40 μmol·L~(-1) and below had no effect on BV2 microglia. THP improved the morphology of BV2 microglia, significantly up-regulated the protein level of α7nAChR, significantly down-regulated the mRNA levels of iNOS, CD86, SOCS3, TNF-α, IL-6, and IL-1β, significantly up-regulated the mRNA levels of Arg-1 and CD206, and dramatically lowered the levels of TNF-α, IL-6, and IL-1β in the cell supernatant. However, the antagonist MLA abolished the above-mentioned ameliorative effects of THP on LPS-treated BV2 microglia. As demonstrated by the aforementioned findings, THP protected LPS-treated BV2 microglia by regulating the M1/M2 polarization and preventing inflammation, which might be connected to the regulation of α7nAChR on BV2 microglia.
